UK markets closed

Ligand Pharmaceuticals Incorporated (LGND)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
70.57+0.20 (+0.28%)
At close: 04:00PM EDT
70.57 0.00 (0.00%)
After hours: 04:02PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 1.27B
Enterprise value 1.10B
Trailing P/E 23.29
Forward P/E 26.32
PEG ratio (5-yr expected) N/A
Price/sales (ttm)9.54
Price/book (mrq)1.81
Enterprise value/revenue 8.40
Enterprise value/EBITDA 11.04

Trading information

Stock price history

Beta (5Y monthly) 0.92
52-week change 3-8.02%
S&P500 52-week change 322.36%
52-week high 394.57
52-week low 349.24
50-day moving average 374.76
200-day moving average 366.93

Share statistics

Avg vol (3-month) 3173.22k
Avg vol (10-day) 3151.82k
Shares outstanding 517.96M
Implied shares outstanding 617.71M
Float 816.69M
% held by insiders 15.93%
% held by institutions 194.49%
Shares short (15 Apr 2024) 4826.61k
Short ratio (15 Apr 2024) 44.18
Short % of float (15 Apr 2024) 46.82%
Short % of shares outstanding (15 Apr 2024) 44.67%
Shares short (prior month 15 Mar 2024) 4876.3k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 402 Jul 2010
Last split factor 21603:1000
Last split date 302 Nov 2022

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 39.72%
Operating margin (ttm)-11.95%

Management effectiveness

Return on assets (ttm)0.79%
Return on equity (ttm)8.29%

Income statement

Revenue (ttm)131.31M
Revenue per share (ttm)7.59
Quarterly revenue growth (yoy)-44.20%
Gross profit (ttm)N/A
EBITDA 45.46M
Net income avi to common (ttm)53.82M
Diluted EPS (ttm)3.03
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)170.31M
Total cash per share (mrq)9.62
Total debt (mrq)6.18M
Total debt/equity (mrq)0.88%
Current ratio (mrq)14.15
Book value per share (mrq)39.92

Cash flow statement

Operating cash flow (ttm)49.58M
Levered free cash flow (ttm)-4.76M